GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...

Congress, held from June 12 to June 15 in Milan, Italy, updated results from the Phase II registrational iMMagine-1 study ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Prof. Musallam’s recognition by EHA affirms his role as a transformative figure in hematology and underscores the UAE’s growing influence in global medical research. His work continues to inspire a ...

Novartis has shared positive results from a phase 3b study of Fabhalta (iptacopan) in a new population of patients with the ...

Explore how health equity and policy shape outcomes, revealing disparities in kidney disease, atopic dermatitis, and cancer care for vulnerable populations.

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukaemia significantly improves patient outcomes post-transplant, reducing ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

First clinical data for INCA033989, a novel monoclonal antibody from Incyte (Nasdaq: INCY) targeting CALR-mutant ...

Phase 2 trial results support Isa-KRd as a standard treatment option for patients with high-risk, newly diagnosed multiple myeloma, according to researchers.